SYN-007 / Theriva Bio - LARVOL DELTA

Early-Life Antibiotic Exposures: Paving the Pathway for Dysbiosis-Induced Disorders. (PubMed, Eur J Pharmacol) - "Addressing dysbiosis incidence requires proactive measures, including prophylactic use of β-lactamase drugs (SYN-004, SYN-006, and SYN-007), hydrolysing the β-lactam in the proximal GIT for maintaining intestinal flora homeostasis...Here, antibiotics-induced microbiota dysbiosis mechanisms and their systemic implications are reviewed. Moreover, proposed interventions to mitigate the impact on gut microflora are also discussed herein."

Journal • Review • Asthma • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Obesity • Oncology • Psychiatry • Pulmonary Disease • Respiratory Diseases • Transplantation

The oral beta-lactamase SYN-007 protects the gut microbiome from damage caused by oral amoxicillin /clavulanate without interfering with amoxicillin systemic absorption in dogs (ECCMID 2019) - "SYN-004 (ribaxamase) is an oral beta-lactamase intended to degrade selected IV beta-lactam antibiotics in the GI tract to protect the microbiome. A Phase 2b clinical study in patients receiving IV ceftriaxone significantly reduced C. difficile infection... SYN-007 protected the gut microbiome from damaged caused by oral administration of amoxicillin/clavulanate without affecting antibiotic systemic absorption. Notably, clavulanate did not interfere with SYN-007-mediated protection of the gut microbiome indicating that clavulanate did not inhibit beta-lactamase activity within the dog GI tract. These data demonstrate that the dual enteric coating formulation of SYN-007 prevented premature release of the beta-lactamase in the upper small intestine while allowing enzyme release soon enough to protect the colonic microbiota."

Gastrointestinal Disorder